Currently Empty: $0.00
CONTENT BLOCKED. The active composition of this product is not disclosed in the catalogue or pricing files and cannot be written to monograph standard until confirmed.
CONTENT BLOCKED. The active composition of this product is not disclosed in the catalogue or pricing files and cannot be written to monograph standard until confirmed.
An investigational triple receptor agonist in late-stage clinical development, producing the largest weight reductions reported for any pharmacological agent to date.
$599.00
CONTENT BLOCKED. The active composition of this product is not disclosed in the catalogue or pricing files and cannot be written to monograph standard until confirmed.
An investigational triple receptor agonist in late-stage clinical development, producing the largest weight reductions reported for any pharmacological agent to date.
$479.00
CONTENT BLOCKED. The active composition of this product is not disclosed in the catalogue or pricing files and cannot be written to monograph standard until confirmed.
A synthetic fragment of human growth hormone studied for its effect on fat metabolism without the glucose effects of full-length HGH.
$125.00
A stabilised GHRH analogue approved by the FDA for the reduction of excess visceral abdominal fat, and one of the best-evidenced compounds in the portfolio.
$130.00